30th Sep 2016 08:41
LONDON (Alliance News) - Midatech Pharma PLC on Friday said the first in-human phase 1 study of a vaccine using its gold nanoparticle technology to treat type-1 diabetes has started.
Midatech, a specialty pharmaceutical firm, said the nano-vaccine, MTX102, uses its gold nano-particle technology. The particles are inert and chemically bound to small antigens which generate a tolerogenic response when injected into the skin, turning down the immune response against the insulin producing cells which cause type 1 diabetes, Midatech said.
The study, results of which are expected in 2017, is the first time these particles have been used in humans.
"I am pleased to be able to announce the start of this important phase I study which uses our GNP technology in an immunotherapy. We are hopeful that this trial will demonstrate the broad applicability of our technology and is exciting for the future of our R&D pipeline," said Midatech Chief Executive Jim Phillips.
Shares in Midatech were up 8.5% at 132.95 pence on Friday morning.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2016 Alliance News Limited. All Rights Reserved.
Related Shares:
MTPH.L